News

Phlow Launches Key Essential Medicines to Leading Children’s Hospitals to Help Alleviate Impact of Shortages

RICHMOND, Va.–(BUSINESS WIRE)–Phlow, a U.S.-based, public benefit impact-driven pharmaceutical company, announced the launch of key essential medicines, sequentially over the coming quarter, for the Children’s Hospital Coalition™ (CHC), a first-in-kind coalition of leading pediatric institutions. The availability of these medications is an important first step demonstrating Phlow’s commitment to CHC members to provide a reliable and affordable supply of high-quality essential medicines to help prevent pediatric drug shortages. “Essential medicines” are defined as those that satisfy the priority health care needs of the American population to sustain life and conquer disease.

“We have worked closely with the CHC to identify critical essential medicines necessary to treat pediatric patients that are either at-risk of, or currently in, shortage,” said Dr. Eric Edwards, CEO of Phlow. “We are thrilled to have an initial portfolio of products going into the hands of children’s hospitals to start the process of bringing certainty and resiliency to the supply chain and we will continue to work with the hospital members to mitigate the impact of shortages.”

Children’s hospitals serve an especially vulnerable population and may struggle to access needed medicines, forcing patients onto alternative therapies or delaying needed treatments. The injectable medications being launched, manufactured through an alliance with Fresenius Kabi USA, include Furosemide Injection, USP, a diuretic which treats fluid retention and swelling; Dexamethasone Sodium Phosphate Injection, USP, a corticosteroid to treat disorders of many organ systems; Heparin Sodium Injection, USP, a blood thinner to prevent and treat blood clots; and Rocuronium Bromide Injection, which is typically given before general anesthesia in preparing for surgery and used to relax the muscles.

“As a founding member of this coalition, I’m excited to see our vision being realized – strengthening the essential medicine supply chain and delivering key pediatric medicines effectively and efficiently to children’s hospitals across the country,” said Dr. Kurt Newman, president and CEO of Children’s National Hospital. “This coalition demonstrates the power of public-private partnerships and how they can effect positive change. I invite more children’s hospitals to join this innovative group addressing pediatric medication shortages.”

The founding members of the CHC, including Phlow, recognize that essential medicine supply is a critical problem in the U.S. and welcome new children’s hospital members to join in this bold initiative.

Read more here.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital